Airways disease: Phenotyping heterogeneity using measures of airway inflammation

Allergy, Asthma and Clinical Immunology

Volumn 3, Issue 2, 2007, Pages 60-69

  Siddiqui, Salman ^a   Brightling, Christopher E ^a,b  

^a Institute of Lung Health   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Asthma; COPD; Eosinophil; Inflammation; Neutrophil

Indexed keywords

BECLOMETASONE DIPROPIONATE; CILOMILAST; CORTICOSTEROID; METHACHOLINE; MOMETASONE FUROATE; PLACEBO; ROFLUMILAST; TRIAMCINOLONE;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; IMMUNOPATHOLOGY; NAUSEA; PHENOTYPE; REVIEW; SPUTUM ANALYSIS; TREATMENT RESPONSE;

EID: 34547862442     PISSN: 17101484     EISSN: None     Source Type: Journal    
DOI: 10.2310/7480.2007.00005     Document Type: Review

References (98)

1. Braman SS. The global burden of asthma. Chest 2006;130(1Suppl):4S-12S.
2. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57.
3. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:499-504.
4. Rosi E, Scano G. Association of sputum parameters with clinical and functional measurements in asthma. Thorax 2000;55:235-8.
5. Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992;47:25-9.
6. Pizzichini E, Pizzichini MM, Leigh R, et al. Safety of sputum induction. Eur Respir J Suppl 2002;37:9s-18s.
7. Efthimiadis A, Spanevello A, Hamid Q, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 2002;37:19s-23s.
8. Juniper EF, Kline PA, Vanzieleghem MA, et al. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990;3:1122-7.
9. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142:832-6.
10. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388-92.
11. Adams NP, Bestall JB, Malouf R, et al. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005;(1):CD002738.
12. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.
13. Man SF, Sin DD. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit? Drugs 2005;65:579-91.
14. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002;109(5 Suppl):S482-9.
15. Mortimer KJ, Tata LJ, Smith CJ, et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006;61:405-8.
16. Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005;94:15-21.
17. Meijer RJ, Postma DS, Kauffman HF, et al. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002;32:1096-103.
18. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999;353:2213-4.
19. Little SA, Chalmers GW, MacLeod KJ, et al. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 2000;55:232-4.
20. ten Brinke A, Zwinderman AH, Sterk PJ, et al. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004;170:601-5.
21. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158(5 Pt 1):1511-7.
22. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-5.
23. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193-8.
24. Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964-71.
25. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;163:406-12.
26. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000;161:64-72.
27. Pizzichini MM, Pizzichini E, Clelland L, et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J 1999;13:15-21.
28. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
29. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483-94.
30. Chlumsky J, Striz I, Terl M, Vondracek J. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006;34:129-39.
31. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997;155:852-7.
32. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(3 Pt 1):822-6.
33. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150(6 Pt 1):1646-52.
34. Confalonieri M, Mainardi E, Della PR, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583-5.
35. O'Donnell RA, Peebles C, Ward JA, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004;59:837-42.
36. Boschetto P, Quintavalle S, Zeni E, et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006;61:1037-42.
37. Siva R, Green R, Brightling CE, et al. Modulation of eosinophilic airway inflammation in COPD. Eur Respir J 2005;26 Suppl 49:441s.
38. O'Donnell RA, Frew AJ. Is there more than one inflammatory phenotype in asthma? Thorax 2002;57:566-8.
39. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002;57:643-8.
40. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001;119:1329-36.
41. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-8.
42. Godon P, Boulet LP, Malo JL, et al. Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids. Eur Respir J 2002;20:1364-9.
43. Berry MA, Morgan A, Green RH, et al. Clinical and pathological features on non-eosinophilic asthma: a distinct asthma phenotype associated with corticosteroid resistance. Thorax 2005;60 Suppl 2:ii4.
44. Brightling CE, Bradding P, Symon FA, et al. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699-705.
45. Chalmers GW, MacLeod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226-30.
46. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006;11:54-61.
47. Turner MO, Hussack P, Sears MR, et al. Exacerbations of asthma without sputum eosinophilia. Thorax 1995;50:1057-61.
48. Anees W, Huggins V, Pavord ID, et al. Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants. Thorax 2002;57:231-6.
49. Belda J, Leigh R, Parameswaran K, et al. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000;161(2 Pt 1):475-8.
50. Thomas RA, Green RH, Brightling CE, et al. The influence of age on induced sputum differential cell counts in normal subjects. Chest 2004;126:1811-4.
51. Chalmers GW, MacLeod KJ, Thomson L, et al. Smoking and airway inflammation in patients with mild asthma. Chest 2001;120:1917-22.
52. Sagel SD, Kapsner R, Osberg I, et al. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001;164(8 Pt 1):1425-31.
53. Nightingale JA, Rogers DF, Hart LA, et al. Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects. Thorax 1998;53:563-71.
54. Simpson JL, Scott RJ, Boyle MJ, Gibson PG. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am J Respir Crit Care Med 2005;172:559-65.
55. Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007;62(3):211-8.
56. Chaudhuri R, Livingston E, McMahon AD, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006;174:127-33.
57. Peleman RA, Rytila PH, Kips JC, et al. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999;13:839-43.
58. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995;152(4 Pt 1):1262-7.
59. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
60. Beeh KM, Beier J, Kornmann O, et al. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003;123:778-83.
61. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Chest 2000;117(5 Suppl 1):262S.
62. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004;125(2 Suppl):41S-50S.
63. Basyigit I, Yildiz F, Ozkara SK, et al. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother 2004;38:1400-5.
64. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.
65. Pesci A, Majori M, Cuomo A, et al. Neutrophils infiltrating bronchial epithelium in chronic obstructive pulmonary disease. Respir Med 1998;92:863-70.
66. Baraldo S, Turato G, Badin C, et al. Neutrophilic infiltration within the ASM in patients with COPD. Thorax 2004;59:308-12.
67. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-71.
68. Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160(5 Pt 1):1635-9.
69. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
70. Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:991-8.
71. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-79.
72. Bundschuh DS, Eltze M, Barsig J, et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90.
73. Spoelstra FM, Berends C, Dijkhuizen B, et al. Effect of theophylline on CD11b and L-selectin expression and density of eosinophils and neutrophils in vitro. Eur Respir J 1998;12:585-91.
74. Au BT, Teixeira MM, Collins PD, Williams TJ. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br J Pharmacol 1998;123:1260-6.
75. Cortijo J, Villagrasa V, Navarrete C, et al. Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim. Br J Pharmacol 1996;119:99-106.
76. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71.
77. Rennard SI, Schachter N, Strek M, et al. Cilomilast for COPD: results of a 6-month, placebo-controlled study. Chest 2006;129:56-66.
78. Gamble E, Grootendorst DC, Brightling CE, et al. Anti-inflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:976-82.
79. Banerjee D, Honeybourne D, Khair OA. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med 2004;3:59-65.
80. Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133-5.
81. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368-70.
82. Dupont LJ, Demedts MG, Verleden GM. Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 2003;123:751-6.
83. Berry MA, Shaw DE, Green RH, et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005;35:1175-9.
84. Payne DN, Adcock IM, Wilson NM, et al. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001;164(8 Pt 1):1376-81.
85. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
86. Shaw DE, Berry MA, Thomas M, et al. Asthma exacerbations and exhaled nitric oxide: a randomised controlled trial. Eur Respir J 2006;28 Suppl 50:572s.
87. Pijnenburg MW, Bakker EM, Hop WC, de Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005;172:831-6.
88. Merkel D, Rist W, Seither P, et al. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005;5:2972-80.
89. Sloane AJ, Lindner RA, Prasad SS, et al. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med 2005;172:1416-26.
90. Kriegova E, Melle C, Kolek V, et al. Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2006;173:1145-54.
91. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003;3:267-75.
92. Wallace AM, He JQ, Burkett KM, et al. Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study. Respir Res 2006;7:76.
93. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 2005;3:431-8.
94. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-9.
95. Wardlaw AJ, Silverman M, Siva R, et al. Multi-dimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy 2005;35:1254-62.
96. Haldar P, Green RH, Berry M, et al. Categorising the asthma phenotype: results of a factor analysis. Thorax 2006;60 Suppl 2:ii53.
97. Hargreave FE, Parameswaran K. Asthma, COPD and bronchitis are just components of airway disease. Eur Respir J 2006;28:264-7.
98. Brightling CE. Clinical applications of induced sputum. Chest 2006;129:1344-8.